This trial is testing a new drug, KIN-2787, for safety and effectiveness in adults with solid tumors that have BRAF or NRAS mutations.
11 Primary · 12 Secondary · Reporting Duration: Initiation of study drug until disease progression (up to approximately 36 months)
Experimental Treatment
155 Total Participants · 5 Treatment Groups
Primary Treatment: KIN-2787 · No Placebo Group · Phase 1
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 60.0% |
Florida | 40.0% |
Did not meet criteria | 80.0% |
Met criteria | 20.0% |
Stanford Cancer Center | 50.0% |
Providence Medical Foundation (St. Joseph's) | 50.0% |
0 | 100.0% |